Selvita to present at Biotech Showcase 2017 in San Francisco
Read More
Selvita presents posters at 2016 EORTC-NCI-AACR Symposium
Read More
FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML
Read More
FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML
Read More
Epidarex Capital Creates Nodthera Limite
Read More
Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory
Read More
Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016
Read More
